Results 181 to 190 of about 755,205 (340)
Naive independent directors, corporate governance and firm performance. [PDF]
Chen G, Chen X, Wan P.
europepmc +1 more source
Genetic Modifiers of Parkinson's Disease: A Case–Control Study
ABSTRACT Objective To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms. Methods We conducted a US‐based observational case–control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases.
Matthew J. Kmiecik +15 more
wiley +1 more source
Corporate governance, capital structure, and firm performance: a panel VAR approach. [PDF]
Ronoowah RK, Seetanah B.
europepmc +1 more source
CODES AND PRACTICES OF IMPLEMENTATION OF CORPORATE GOVERNANCE IN ROMANIA AND RESULTS REPORTING [PDF]
Corporate governance refers to the manner in which companies are directed and controlled. Business management was always guided by certain principles, but the current meaning of corporate governance concerns and the contribution that companies must have ...
GROSU MARIA
core
Corporate risk disclosure is one of the strategic issues in efforts to optimize the role of corporate governance in state-owned enterprises in Indonesia.
Anggita Langgeng WIJAYA
doaj +1 more source
ABSTRACT The pathogenesis of Sydenham chorea remains unclear. We report a 10‐year‐old girl presenting with subacute chorea and mild carditis following Streptococcal throat infection. Single‐cell RNA sequencing on 30,794 peripheral immune cells from the patient and two sex‐matched controls revealed nine immune cell clusters.
Velda X. Han +9 more
wiley +1 more source
The Symbolic Management of Stockholders: Corporate Governance Reforms and Shareholder Reactions
James D. Westphal, Edward J. Zajac
openalex +2 more sources
Environmental contingencies and sustainable modes of corporate governance [PDF]
Neil Garrod
openalex +1 more source
Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data
ABSTRACT Objective Therapeutic development for mitochondrial diseases, rare genetic disorders with pathogenic defects of oxidative phosphorylation, is hindered by unsatisfactory outcome measures. To address this problem, we provide the first clinical application of a novel, bias‐adjusted outcome measure of acceleration across a range of subjects ...
Ian W. McKeague +8 more
wiley +1 more source

